Botanix is an ASX-listed dermatology company based in Philadelphia and Phoenix (USA) that is committed to the development and commercialisation of novel treatments for common skin diseases and infections. The company’s lead product is a novel treatment for primary axillary hyperhidrosis, a medical condition where excessive sweating occurs beyond what is needed to maintain body temperature, which impacts the lives of more than 15 million people in the US alone. This product is backed by successful Phase 3 clinical studies, is already approved in Japan, and is in the final stages of US regulatory clearance. The broader clinical pipeline targets unmet needs in dermatology (including acne, rosacea and dermatitis) as well as infections, and are underpinned by well-controlled, randomised clinical trials. Botanix has attracted a world-class team and significant capital to support the development and commercialisation of its products.
